Full Press Release Details
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union.
BIIB
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Key Takeaway: Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Price reaction · baseline $146.23 (2025-01-30 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
-1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis